 "Marksans Pharma surges on USFDA nod for Loratadine")
Marksans Pharma has moved higher by 12% to Rs 53.55 on the BSE after the company announced that it has got US drug regulator nod for loratadine liquid filed capsules 10 mg.
“The US Food & Drug Administration (USFDA) has granted approval for an Abbreviated New Drug Application (ANDA) for Loratadine liquid filed capsules 10 mg,” Marksans Pharma said in a press release.
Loratadine liquid filed capsules 10 mg is therapeutically equivalent to the reference listed drug Claritin Liqui-Gels Capsules 10 mg of Bayer Healthcare LLC.
Loratadine is an antihistamine that reduces the effects of natural chemical histamine in the body. Loratadine is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms.
Thus far in September, the stock outperformed the market by surging 31% from Rs 40.75, as compared to 0.22% rise in the S&P BSE Sensex.
At 11:03 am, the stock was up 11% at Rs 53.10, against 0.53% decline in the benchmark index. The counter has seen huge trading volumes with a combined 12.43 million shares changing hands on the BSE and NSE so far.
“The US Food & Drug Administration (USFDA) has granted approval for an Abbreviated New Drug Application (ANDA) for Loratadine liquid filed capsules 10 mg,” Marksans Pharma said in a press release.
Loratadine liquid filed capsules 10 mg is therapeutically equivalent to the reference listed drug Claritin Liqui-Gels Capsules 10 mg of Bayer Healthcare LLC.
Loratadine is an antihistamine that reduces the effects of natural chemical histamine in the body. Loratadine is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms.
Thus far in September, the stock outperformed the market by surging 31% from Rs 40.75, as compared to 0.22% rise in the S&P BSE Sensex.
At 11:03 am, the stock was up 11% at Rs 53.10, against 0.53% decline in the benchmark index. The counter has seen huge trading volumes with a combined 12.43 million shares changing hands on the BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%